Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Glob Infect Dis ; 3(3): 254-8, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21887057

RESUMO

BACKGROUND: Stenotrophomonas maltophilia, previously named as Pseudomonas or Xanthomonas maltophilia, is an important nosocomial pathogen AIM: The purpose of the present study was to investigate the prevalence of S. maltophilia in Iranian hospitals and its susceptibility to available antimicrobial agents. SETTING AND DESIGN: A cross-sectional study in Imam Khomeini Hospital affiliated to Tehran University of Medical Sciences. MATERIALS AND METHODS: All blood specimens were sent to the laboratory for blood culture and biochemical analysis. One hundred samples were positive for S. maltophilia. We used disk diffusion and E-test in order to determine minimal inhibitory concentration (MIC) of ceftazidime and co-trimoxazole as the first line antibiotics for S. maltophilia. The tests were performed and interpreted according to the guidelines of Clinical Laboratory Standards Institute (CLSI). STATISTICAL ANALYSIS: Chi-square test and Kappa measurement of agreement were applied as appropriate. RESULTS: S. maltophilia was the most frequent pathogen (895 specimens; 38.9%) isolated from the samples which were mostly from emergency ward (780 specimens; 33.9%). Ceftazidime MIC(50) and MIC(90) were 2 and 32 µg/ml, respectively (sensitive ≤8 µg/ml and resistant ≥32 µg/ml according to CLSI guideline). MIC(50) and MIC(90) for co-trimoxazole were 0.5 and 2 µg/ml, respectively (sensitive ≤2 µg/ml and resistant ≥4 µg/ml according to CLSI guideline). CONCLUSION: S. maltophilia is the most frequent pathogen in our hospital with a high susceptibility to both ceftazidime and co-trimoxazole.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...